Open Payments

PARESH C GIRI

Type
Physician · Allopathic & Osteopathic Physicians / Internal Medicine
Where
YUCAIPA, CA
NPI
1346497245
Received
$39,230 in 78 records, 2019 to 2025
As principal investigator
$155,161 of research payments to others in 55 records
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment10$4,930
2024General payment10$5,016
2023General payment4$2,604
2022General payment17$4,641
2021General payment5$5,179
2020General payment13$7,942
2019General payment19$8,915

By company

CompanyRecordsAmountYears
United Therapeutics Corporation52$37,6302019–2025
Actelion Pharmaceuticals US, Inc.19$1,1072019–2025
Inari Medical, Inc.2$3902022
Merck Sharp & Dohme LLC2$482023–2025
Bayer Healthcare Pharmaceuticals Inc.2$292019–2020
Genentech, Inc.1$242019

By nature of payment

NatureRecordsAmount
Compensation for services other than consulting, including serving as faculty or as a speaker at a v26$35,724
Food and Beverage50$2,530
Consulting Fee1$970
Education1$5

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-24United Therapeutics Corporation$970Consulting FeeCash or cash equivalent2025
2025-12-03United Therapeutics Corporation$8Food and BeverageIn-kind items and servicesTyvaso Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease2025
2025-10-21Actelion Pharmaceuticals US, Inc.$45Food and BeverageIn-kind items and servicesUPTRAVI Drug, Cardiology2025
2025-10-20United Therapeutics Corporation$42Food and BeverageIn-kind items and services2025
2025-10-08United Therapeutics Corporation$16Food and BeverageIn-kind items and servicesTyvaso Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease2025
2025-06-24United Therapeutics Corporation$1,270Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease2025
2025-05-14United Therapeutics Corporation$7Food and BeverageIn-kind items and servicesTyvaso Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease2025
2025-04-15United Therapeutics Corporation$1,270Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease2025
2025-04-04Merck Sharp & Dohme LLC$30Food and BeverageIn-kind items and servicesWINREVAIR Biological, CARDIOVASCULAR2025
2025-03-24United Therapeutics Corporation$1,270Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease2025
2024-12-17United Therapeutics Corporation$485Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-10-24United Therapeutics Corporation$9Food and BeverageIn-kind items and servicesTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease2024
2024-10-06Actelion Pharmaceuticals US, Inc.$102Food and BeverageIn-kind items and servicesUPTRAVI Drug, Cardiology2024
2024-10-06United Therapeutics Corporation$28Food and BeverageIn-kind items and services2024
2024-07-08United Therapeutics Corporation$1,270Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease2024
2024-06-30Actelion Pharmaceuticals US, Inc.$100Food and BeverageIn-kind items and servicesUPTRAVI Drug, Cardiology2024
2024-04-30United Therapeutics Corporation$1,698Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease2024
2024-04-29United Therapeutics Corporation$24Food and BeverageIn-kind items and services2024
2024-01-24United Therapeutics Corporation$1,270Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease2024
2024-01-18United Therapeutics Corporation$28Food and BeverageIn-kind items and servicesTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease2024
2023-11-14United Therapeutics Corporation$1,270Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentTYVASO Drug, PAH2023
2023-10-25United Therapeutics Corporation$1,270Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentTYVASO Drug, PAH2023
2023-10-25Merck Sharp & Dohme LLC$17Food and BeverageIn-kind items and services2023
2023-10-08United Therapeutics Corporation$46Food and BeverageIn-kind items and servicesTYVASO Drug, PAH2023
2022-11-29United Therapeutics Corporation$1,270Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentTYVASO Drug, PAH2022
2022-11-29United Therapeutics Corporation$23Food and BeverageIn-kind items and servicesTYVASO Drug, PAH2022
2022-11-17United Therapeutics Corporation$2Food and BeverageIn-kind items and servicesTYVASO Drug, PAH2022
2022-10-17Actelion Pharmaceuticals US, Inc.$55Food and BeverageIn-kind items and servicesUPTRAVI Drug, Cardiology2022
2022-10-16Actelion Pharmaceuticals US, Inc.$144Food and BeverageIn-kind items and servicesUPTRAVI Drug, Cardiology2022
2022-10-16Actelion Pharmaceuticals US, Inc.$72Food and BeverageIn-kind items and servicesUPTRAVI Drug, Cardiology2022
2022-10-15Actelion Pharmaceuticals US, Inc.$120Food and BeverageIn-kind items and servicesOPSUMIT Drug, Cardiology2022
2022-10-15Actelion Pharmaceuticals US, Inc.$120Food and BeverageIn-kind items and servicesOPSUMIT Drug, Cardiology2022
2022-09-01United Therapeutics Corporation$4Food and BeverageIn-kind items and servicesTYVASO Drug, PAH2022
2022-07-08Inari Medical, Inc.$34Food and BeverageIn-kind items and servicesFLOWTRIEVER CATHETER, S Device, VTE2022
2022-07-06Inari Medical, Inc.$356Food and BeverageIn-kind items and servicesFLOWTRIEVER CATHETER, S Device, VTE2022
2022-07-06Actelion Pharmaceuticals US, Inc.$23Food and BeverageIn-kind items and servicesUPTRAVI Drug, Cardiology2022
2022-04-22United Therapeutics Corporation$1,025Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2022
2022-04-01United Therapeutics Corporation$102Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2022
2022-03-09United Therapeutics Corporation$1,270Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentORENITRAM Drug, PAH2022
2022-02-12Actelion Pharmaceuticals US, Inc.$11Food and BeverageIn-kind items and servicesOPSUMIT Drug, Cardiology2022
2022-01-18United Therapeutics Corporation$5Food and BeverageIn-kind items and servicesTYVASO Drug, PAH2022
2021-12-13Actelion Pharmaceuticals US, Inc.$13Food and BeverageIn-kind items and servicesOPSUMIT Drug, Cardiology2021
2021-09-02United Therapeutics Corporation$2,500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2021
2021-09-02United Therapeutics Corporation$125Food and BeverageIn-kind items and services2021
2021-09-01United Therapeutics Corporation$1,270Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2021
2021-06-29United Therapeutics Corporation$1,270Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentORENITRAM Drug, PAH2021
2020-11-25Bayer Healthcare Pharmaceuticals Inc.$15Food and BeverageIn-kind items and servicesAdempas Drug, Cardio-pulmonary2020
2020-11-11United Therapeutics Corporation$1,270Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentORENITRAM Drug, PAH2020
2020-10-27United Therapeutics Corporation$1,270Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentORENITRAM Drug, PAH2020
2020-05-28United Therapeutics Corporation$870Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentORENITRAM Drug, PAH2020
2020-05-11United Therapeutics Corporation$5EducationIn-kind items and services2020
2020-05-01United Therapeutics Corporation$114Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentORENITRAM Drug, PAH2020
2020-03-09Actelion Pharmaceuticals US, Inc.$5Food and BeverageIn-kind items and servicesUPTRAVI Drug, Cardiology2020
2020-02-28United Therapeutics Corporation$3,300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-02-27United Therapeutics Corporation$103Food and BeverageIn-kind items and services2020
2020-02-27United Therapeutics Corporation$10Food and BeverageIn-kind items and services2020
2020-02-24United Therapeutics Corporation$840Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-01-30Actelion Pharmaceuticals US, Inc.$12Food and BeverageIn-kind items and servicesUPTRAVI Drug, Cardiology2020
2020-01-14Actelion Pharmaceuticals US, Inc.$124Food and BeverageIn-kind items and servicesUPTRAVI Drug, Cardiology2020
2019-12-23Bayer Healthcare Pharmaceuticals Inc.$14Food and BeverageIn-kind items and servicesAdempas Drug, Cardio-pulmonary2019
2019-12-13United Therapeutics Corporation$3Food and BeverageIn-kind items and servicesORENITRAM Drug, PAH2019
2019-12-13United Therapeutics Corporation$2Food and BeverageIn-kind items and servicesORENITRAM Drug, PAH2019
2019-11-18United Therapeutics Corporation$840Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentORENITRAM Drug, PAH2019
2019-11-14United Therapeutics Corporation$3,300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentORENITRAM Drug, PAH2019
2019-11-14United Therapeutics Corporation$98Food and BeverageIn-kind items and servicesORENITRAM Drug, PAH2019
2019-09-17Actelion Pharmaceuticals US, Inc.$15Food and BeverageIn-kind items and servicesUPTRAVI Drug, Cardiology2019
2019-08-28Actelion Pharmaceuticals US, Inc.$67Food and BeverageIn-kind items and servicesOPSUMIT Drug, CARDIOVASCULAR DISORDERS2019
2019-06-20United Therapeutics Corporation$118Food and BeverageIn-kind items and servicesORENITRAM Drug, PAH2019
2019-05-20Actelion Pharmaceuticals US, Inc.$29Food and BeverageIn-kind items and servicesBOSENTAN Drug, Pulmonary Hypertension2019
2019-05-19Genentech, Inc.$24Food and BeverageIn-kind items and servicesEsbriet Biological, Immunology2019
2019-04-23United Therapeutics Corporation$840Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentORENITRAM Drug, PAH2019
2019-03-24United Therapeutics Corporation$5Food and BeverageIn-kind items and servicesREMODULIN Drug, PAH2019
2019-03-12Actelion Pharmaceuticals US, Inc.$16Food and BeverageIn-kind items and servicesOPSUMIT Drug, Cardiology2019
2019-02-26United Therapeutics Corporation$11Food and BeverageIn-kind items and servicesORENITRAM Drug, PAH2019
2019-02-19United Therapeutics Corporation$3,300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREMODULIN Drug, PAH2019
2019-02-19United Therapeutics Corporation$90Food and BeverageIn-kind items and servicesREMODULIN Drug, PAH2019
2019-01-22Actelion Pharmaceuticals US, Inc.$25Food and BeverageIn-kind items and servicesUPTRAVI Drug, Cardiology2019
2019-01-10United Therapeutics Corporation$111Food and BeverageIn-kind items and servicesTYVASO Drug, PAH2019

Research payments naming this person as principal investigator

DateCompanyPaid toAmountStudyYear
2025-12-15United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$180A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE2025
2023-08-16United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$7,628A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF RALINEPAG TO EVALUATE SAFETY AND EFFECTS ON EXERCISE CA2023
2023-05-19United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$420A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE2023
2023-04-14United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$420A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE2023
2023-03-17United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$420A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE2023
2023-03-06United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$1,300A STUDY EVALUATING THE LONG-TERM EFFICACY AND SAFETY OF RALINEPAG IN SUBJECTS WITH PAH VIA AN OPEN-LABEL EXTENSION2023
2023-03-06United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$1,300A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE2023
2023-03-06United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$1,300A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE2023
2023-03-06United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$390A STUDY EVALUATING THE LONG-TERM EFFICACY AND SAFETY OF RALINEPAG IN SUBJECTS WITH PAH VIA AN OPEN-LABEL EXTENSION2023
2023-03-06United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$390A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE2023
2023-03-06United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$1,300A STUDY EVALUATING THE LONG-TERM EFFICACY AND SAFETY OF RALINEPAG IN SUBJECTS WITH PAH VIA AN OPEN-LABEL EXTENSION2023
2023-02-03United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$7,500A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF RALINEPAG TO EVALUATE SAFETY AND EFFECTS ON EXERCISE CA2023
2023-02-03United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$3,900A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF RALINEPAG TO EVALUATE SAFETY AND EFFECTS ON EXERCISE CA2023
2022-11-23United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$1,681A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE2022
2022-11-04United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$1,316A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE2022
2022-07-18United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$1,699A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE2022
2022-06-20United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$420A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE2022
2022-05-23United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$1,699A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE2022
2022-03-21United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$1,699A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE2022
2022-02-16United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$1,950A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE2022
2022-01-24United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$1,699A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE2022
2021-11-23United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$2,539A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE2021
2021-08-23United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$1,699A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE2021
2021-06-21United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$420A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE2021
2020-11-24United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$1,699A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients2020
2020-09-22United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$1,278A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients2020
2020-08-25United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$6,266A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients2020
2020-08-10Actelion Pharmaceuticals, LtdLoma Linda Univ Hlth$1,300OPsumit Users Registry2020
2020-08-10Actelion Pharmaceuticals, LtdLoma Linda Univ Hlth$200OPsumit Users Registry2020
2020-07-23United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$97A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients2020
2020-07-13Actelion Pharmaceuticals, LtdLoma Linda Univ Hlth$28,375OPsumit Users Registry2020
2020-07-07United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$97A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension2020
2020-07-07United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$97A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients2020
2020-06-23United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$97A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension2020
2020-06-23United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$97A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients2020
2020-06-04United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$2,101A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients2020
2020-05-21United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$97A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension2020
2020-05-14United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$97A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients2020
2020-05-05United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$97A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension2020
2020-05-05United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$97A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients2020
2020-04-14United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$1,662A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients2020
2020-03-24United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$4,124A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients2020
2020-03-05United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$97A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients2020
2020-03-05United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$97A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension2020
2020-03-03United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$1,950A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients2020
2020-03-03United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$97A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients2020
2020-03-03United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$520A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients2020
2020-01-23United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$97A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension2020
2020-01-14United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$97A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients2020
2020-01-07United Therapeutics CorporationLOMA LINDA UNIVERSITY HEALTH (LLUH)$520A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients2020
2019-10-28Actelion Pharmaceuticals, LtdLOMA LINDA UNIVERSITY ADVENTIST HEALTH SCIENCES CTR$13,100OPUS - AC-055-5032019
2019-08-05Actelion Pharmaceuticals, LtdLOMA LINDA UNIVERSITY ADVENTIST HEALTH SCIENCES CTR$20,900OPUS - AC-055-5032019
2019-06-03Actelion Pharmaceuticals, LtdLoma Linda University$12,625OPUS - AC-055-5032019
2019-02-11Actelion Pharmaceuticals, LtdLoma Linda University$12,600OPUS - AC-055-5032019
2019-02-11Actelion Pharmaceuticals, LtdLoma Linda University$1,300OPUS - AC-055-5032019

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

San Bernardino CountyYucaipa city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Yucaipa, CA, county San Bernardino County, CA, state California; placed by its city name.

MeasurePlace (city or town)
Yucaipa, CA
County
San Bernardino County, CA
State
California
Population B0100354,4212,197,10439,287,377
Population, 2020 census P154,5422,181,65439,538,223
Median age B0100236.334.737.9
Under 18 B0100126.2%25.5%22.0%
65 and over B0100116.0%12.6%15.7%
Households B1100118,506674,91513,548,091
Foreign born B0500210.7%21.6%27.0%
Median household income B19013$90,794$85,478$99,122
Median family income B19113$108,424$93,416$113,346
Per capita income B19301$39,987$34,343$49,513
Poverty rate B170019.1%13.3%12.0%
Unemployment rate B230257.0%7.1%6.6%
Civilian labor force B2302525,9651,046,62420,068,466
Mean commute (minutes) B0801332.632.628.7
Bachelor's degree or higher B1500326.9%23.3%37.1%
Housing units B2500119,248743,88614,644,735
Owner-occupied B2500373.4%62.1%55.9%
Renters B2500326.6%37.9%44.1%
Median home value B25077$502,100$505,000$734,700
Median gross rent B25064$1,711$1,801$2,036
White, not Hispanic B0300253.9%24.7%33.8%
Black B030021.1%7.5%5.2%
Hispanic or Latino B0300236.3%55.2%40.2%
Asian B030023.2%8.1%15.3%
American Indian and Alaska Native B030020.2%0.3%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.0% in Oct 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Yucaipa, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.